Search
Viral Vectors
DNA
Antibiotic-free Maintenance System (ORT®)
Microbiota
Technical Protein
Fill Finish
Search
About
Events
Our Commitment to You
Our Mission & Values
Code of Conduct
Project Management
Quality Assurance
Our History
Sustainability
Careers
News
Contact Us
Select Language
Español
Deutsch
한국의
Français
Svenska
中国的
日本の
Menu
News
Discover the latest news stories, blog posts and publications from Cobra's expert team
Home
/
News
Toggle filters
Posts by Tag
August 2020
(5)
November 2017
(4)
April 2020
(4)
May 2013
(3)
October 2013
(3)
April 2017
(3)
July 2017
(3)
January 2018
(3)
November 2019
(3)
March 2020
(3)
October 2020
(3)
February 2021
(3)
June 2011
(2)
October 2011
(2)
February 2012
(2)
June 2012
(2)
October 2012
(2)
March 2013
(2)
February 2014
(2)
March 2014
(2)
June 2014
(2)
February 2015
(2)
September 2015
(2)
June 2016
(2)
November 2016
(2)
January 2017
(2)
December 2017
(2)
February 2018
(2)
March 2018
(2)
September 2018
(2)
October 2019
(2)
January 2021
(2)
January 2011
(1)
February 2011
(1)
July 2011
(1)
September 2012
(1)
November 2012
(1)
January 2013
(1)
June 2013
(1)
August 2013
(1)
December 2013
(1)
January 2014
(1)
April 2014
(1)
May 2014
(1)
September 2014
(1)
December 2014
(1)
March 2015
(1)
April 2015
(1)
May 2015
(1)
July 2015
(1)
August 2015
(1)
November 2015
(1)
February 2016
(1)
March 2016
(1)
May 2016
(1)
July 2016
(1)
October 2016
(1)
March 2017
(1)
May 2017
(1)
September 2017
(1)
October 2017
(1)
April 2018
(1)
May 2018
(1)
June 2018
(1)
October 2018
(1)
November 2018
(1)
January 2019
(1)
June 2019
(1)
September 2019
(1)
January 2020
(1)
June 2020
(1)
September 2020
(1)
December 2020
(1)
March 2021
(1)
See all
or
Posts by Tag
Gene Therapy
(24)
General
(22)
DNA
(18)
blog
(16)
Viral Vectors
(14)
vaccine
(13)
COVID-19
(11)
Awards
(9)
Coronavirus
(9)
Collaboration
(8)
Manufacturing
(8)
cell therapy
(8)
expansion
(8)
business
(7)
gene
(7)
therapy
(7)
award
(6)
international trade
(6)
AAV
(5)
CombiGene
(5)
immunotherapy
(5)
investment
(5)
plasmid dna
(5)
Cobra Biologics
(4)
Cognate BioServices
(4)
Innovate UK
(4)
News
(4)
Proteins
(4)
STEM
(4)
University
(4)
acquisition
(4)
development
(4)
#21Cmed
(3)
Advanced Therapy Medicinal Product
(3)
Alligator
(3)
Bionow
(3)
CG01
(3)
CMO
(3)
CPI
(3)
Featured
(3)
Innovate
(3)
adeno-associated virus
(3)
cell
(3)
clinical trials
(3)
epilepsy
(3)
export
(3)
grant
(3)
jobs
(3)
maxXpress
(3)
process
(3)
viral
(3)
A-level choices
(2)
ATMP
(2)
Advanced Therapies Manufacturing Taskforce
(2)
Careers in Science
(2)
Centre for Process Innovation
(2)
Charles River
(2)
Expertise
(2)
Finalists
(2)
GCSE options
(2)
GE Healthcare
(2)
GMP
(2)
Immune-oncology
(2)
Immuno-Oncology
(2)
Industrial Strategy
(2)
Manchester
(2)
Pharma
(2)
Quality
(2)
Queen's Award
(2)
Staffordshire
(2)
Trade
(2)
UK medicine
(2)
antibody
(2)
articles
(2)
bacteria
(2)
biologics
(2)
biopharmaceuticals
(2)
branding
(2)
cell line development
(2)
clinical
(2)
competition
(2)
education
(2)
expression
(2)
interview
(2)
medicine
(2)
microbioreactor
(2)
oxford
(2)
peer reviewed
(2)
plasmid
(2)
regenerative
(2)
science
(2)
single-use
(2)
vector
(2)
vectors
(2)
viral vector
(2)
vlog
(2)
ADC-1013
(1)
ADCs
(1)
ATAC
(1)
AstraZeneca
(1)
BioSpace
(1)
Bioscience
(1)
CAR-T
(1)
CDMO
(1)
CSO
(1)
Cancer
(1)
Capabilities
(1)
Capsules
(1)
Cell and Gene Therapy Catapult
(1)
Chambers
(1)
Cobra
(1)
Commerce
(1)
Compatibility
(1)
Director
(1)
Engineered
(1)
Future
(1)
Highlights
(1)
Innovation
(1)
Internal
(1)
Leukoencephalopathy
(1)
MHRA
(1)
Manufacturer
(1)
Multifocal
(1)
NEUWAY
(1)
Pall Corporation
(1)
ProFuse
(1)
Progressive
(1)
Puridify
(1)
Reliability
(1)
Sartorius
(1)
Sheffield
(1)
Staffs
(1)
Stedim
(1)
SwedenBIO
(1)
Symbiosis
(1)
Technologies
(1)
Tokyo
(1)
Tony Hitchcock
(1)
Touchlight
(1)
UCOE
(1)
UKTI
(1)
Viruses
(1)
Webinar
(1)
YEOTY
(1)
adenovirus
(1)
advanced
(1)
alevel choices
(1)
antibodies
(1)
apprenticeships
(1)
baculovirus
(1)
bioreactor
(1)
careers
(1)
cmo leadership award
(1)
commercial supply
(1)
compliance
(1)
costs
(1)
covid19
(1)
degree choices
(1)
department
(1)
disease
(1)
disposables
(1)
event
(1)
goals
(1)
growth
(1)
jenner institute
(1)
leadership
(1)
life
(1)
line
(1)
microbial
(1)
mobile
(1)
neurodegenerative
(1)
new website
(1)
of
(1)
operations
(1)
orphan
(1)
partnership
(1)
partnerships
(1)
processes
(1)
promising technologist
(1)
protein
(1)
rare
(1)
rare disease day
(1)
regulatory
(1)
relationship
(1)
responsive
(1)
risk
(1)
scancell
(1)
scientist
(1)
service
(1)
social media
(1)
solid
(1)
studies
(1)
study
(1)
supply
(1)
survey
(1)
technology
(1)
therapeutics
(1)
timelines
(1)
toxicity
(1)
trial
(1)
trials
(1)
tumours
(1)
visitor experience
(1)
web design
(1)
website
(1)
See all
Posts about
Gene Therapy
Charles River Laboratories Completes the Acquisition of Cognate BioServices
Featured
,
Gene Therapy
,
cell therapy
,
acquisition
,
Charles River
The acquisition establishes Charles River as a premier scientific partner for cell and gene therapy development, testing, and manufacturing, providing clients with an integrated solution from basic research and discovery through CGMP production.
Charles River to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development
Gene Therapy
,
cell therapy
,
acquisition
,
Charles River
Significantly Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector & Combines Cognate’s Comprehensive Cell and Gene Therapy CDMO Capabilities to Establish an Integrated Solution from Discovery through CGMP Manufacturing
Cognate BioServices, and its gene therapy division Cobra Biologics Announce Major Expansion of Manufacturing Facilities in US and Europe
Gene Therapy
,
ATMP
,
expansion
,
cell therapy
,
Cognate BioServices
This includes a four-fold increase in HQ (High Quality) DNA manufacturing capacity alongside new clinical and commercial GMP DNA facilities at its European facilities
CombiGene and Cobra Biologics sign agreement to secure GMP production of plasmids for production of CombiGene's gene therapy CG01
Gene Therapy
,
CombiGene
,
plasmid dna
,
CG01
,
epilepsy
The agreement is part of preparations for GMP production of material for the first clinical study of CG01
Cobra Biologics completes production of Master Cell Banks for CombiGene’s epilepsy gene therapy drug candidate
Gene Therapy
,
CombiGene
,
plasmid dna
,
CG01
,
epilepsy
Foundation for future commercial supply of CG01 secured with delivery of three Master Cell Banks
Cobra Biologics delivers final plasmids for production of CG01 in CombiGene's epilepsy project
Gene Therapy
,
CombiGene
,
plasmid dna
,
CG01
,
epilepsy
Further milestone paves the way for production of novel gene therapy drug candidate designed to treat drug-resistant focal epilepsy
Cobra Biologics successfully completes key milestone in CombiGene’s epilepsy project CG01 with delivery of first DNA plasmid
Gene Therapy
,
News
,
CombiGene
,
plasmid dna
Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy
Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy
Cognate BioServices closes Series B and completes acquisition of Cobra Biologics
Gene Therapy
,
General
,
cell therapy
,
acquisition
,
Cognate BioServices
This transaction further supports Cognate's mission to meet the needs of the ultimate consumer of its services — the patients with unmet medical needs
Cognate BioServices announces acquisition of Cobra Biologics
Gene Therapy
,
General
,
cell therapy
,
acquisition
,
Cognate BioServices
Transformative acquisition creates global cell and gene therapy manufacturing services platform for both clinical and commercial products
aaaaa
CPI Accelerates Gene Therapy Development with Robust Adeno-Associated Virus Purification System in Partnership with Cobra Biologics and GE Healthcare
Viral Vectors
,
Gene Therapy
,
Collaboration
,
CPI
,
AAV
,
Innovate
,
Centre for Process Innovation
,
GE Healthcare
,
adeno-associated virus
The new process will remove a significant bottleneck in the development of gene therapies, and enable these innovative products to be brought to market more quickly.
CPI has announced the success of its CRD IUK project to develop a scalable, cost-effective purification process for adeno-associated viruses (AAVs), in partnership with Cobra Biologics and GE Healthcare Life Sciences. The new process will remove a significant bottleneck in the development of gene therapies, and enable these innovative products to be brought to market more quickly.
CombiGene signs agreement with Cobra Biologics for production of candidate drug CG01
Viral Vectors
,
Gene Therapy
,
Collaboration
,
AAV
,
CombiGene
Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials
(Svensk version nedan)
1
2
3